T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter: 4 X users

patent: 2 patents

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

NOVEL BIOMARKER FOR CANCER IMMUNOTHERAPY

Application EP-3597766-A4

European Patent Office

USE OF IMMUNE DIVERSITY AS A PREDICTIVE MARKER FOR IDENTIFYING PATIENTS LIKELY TO RESPOND…

Application WO-2015162596-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.